New in CME courses: Targeting Molecular Mechanisms in Patients with Metastatic Breast Cancer: Inhibiting Estrogen Receptor-Induced Proliferation

Target audience:  Oncologists, surgeons, ONS nurses, and other healthcare providers involved in the treatment of patients with breast cancer.

The complexity of breast cancer continues to be revealed

Ten-year breast-cancer (BC) mortality rates are reduced by a third with hormone therapy, meaning that more than half of patients with ER-positive breast cancer will have either de novo or will develop acquired resistance to endocrine therapy. This reflects both the progress made to date and the ongoing challenges faced by both researchers and clinicians. Oncologists need to refine their knowledge of the role of molecules and pathways involved in BC pathogenesis to better understand the science supporting targeted therapies and their combinations.

The goal of the following activity is to enhance your knowledge of the underlying pathology of HR+ advanced/metastatic breast cancer, build on your current knowledge of both hormonal and targeted agents, and apply evidence-based individualized treatment plans using patient cases, faculty discussion, and feedback.

This activity – Targeting Molecular Mechanisms in Patients with Metastatic Breast Cancer: Inhibiting Estrogen Receptor-Induced Proliferation, offers: 1.0 AMA PRA Category 1 Credit™, 1 ANCC contact hour.

Click here to start this activity!